EGFR and non-small cell lung carcinoma: Based on both safety profile and clinical activities of patritumab Process 1 combined with EGFR-TKI, erlotinib in patients with advanced NSCLC, this study evaluated that the safety and pharmacokinetics of patritumab Process 2 in combination with erlotinib and potential biomarkers related to patritumab were also evaluated.